Medication-Assisted Treatment (MAT): How It Works, Medications, and Who It Helps

Medication-assisted treatment (MAT) is an evidence-based approach to treating opioid use disorder and alcohol use disorder.

MAT combines FDA-approved medications with counseling and behavioral therapy. SAMHSA, the CDC, the World Health Organization, and the American Society of Addiction Medicine all endorse MAT as the most effective available treatment for opioid use disorder.

MAT is not “replacing one addiction with another.” The medications used in MAT either partially activate opioid receptors to blunt craving and withdrawal without producing euphoria, or block receptors entirely to prevent the reinforcing effects of opioids.

They are prescribed and monitored by licensed clinicians and do not produce the chaotic reward cycling that sustains addiction.

Key Takeaways

• According to SAMHSA, MAT reduces opioid use, criminal activity, infectious disease transmission, and overdose death while significantly improving treatment retention rates compared to behavioral therapy alone.
• People who receive buprenorphine or methadone as part of MAT have 50 to 80% lower risk of drug overdose, particularly among those with fentanyl use disorder, according to data published by SAMHSA.
• There are three FDA-approved medications for opioid use disorder: methadone, buprenorphine (Suboxone/Sublocade), and naltrexone (Vivitrol), each working through a different mechanism.
• The newer preferred term is MOUD (medications for opioid use disorder), which NIDA and SAMHSA increasingly use to reflect that medication is a core clinical intervention, not merely a supporting tool.
• MAT is considered the standard of care for opioid use disorder by SAMHSA, the CDC, ASAM, and the WHO, yet it remains underutilized, fewer than 20% of people with OUD receive any FDA-approved medication.

What Is Medication-Assisted Treatment?

Medication-assisted treatment is a structured treatment model that integrates pharmacological agents, medications that directly act on the neurochemical systems disrupted by addiction, with evidence-based behavioral therapies such as cognitive behavioral therapy, motivational interviewing, and 12-step facilitation.

MAT directly targets what makes opioid use disorder and alcohol use disorder so difficult to treat without medication: the neurobiological withdrawal state and the protracted craving cycle that persist for months to years after the last use.

MAT vs. MOUD: What’s the Difference?

MAT (medication-assisted treatment) has been the clinical standard term for decades. MOUD (medications for opioid use disorder) is a newer term adopted by NIDA, SAMHSA, and the FDA to specifically describe the use of methadone, buprenorphine, and naltrexone for opioid use disorder.

The shift in language reflects an updated clinical position: medication is not simply “assisting” behavioral treatment it is a primary, evidence-based intervention with documented outcomes independent of concurrent counseling. Both terms remain in wide clinical and regulatory use.

What Conditions Does MAT Treat?

MAT has strong evidence for two categories of substance use disorder:

• Opioid use disorder (OUD): MAT is the standard of care for OUD. The three FDA-approved medications address the mu-opioid receptor adaptations that drive withdrawal, craving, and relapse. According to the National Institute on Drug Abuse, untreated OUD carries mortality rates significantly higher than OUD treated with buprenorphine or methadone.
• Alcohol use disorder (AUD): Three FDA-approved medications treat AUD through distinct mechanisms. Naltrexone blocks alcohol’s reward response, acamprosate stabilizes glutamate activity to reduce protracted craving, and disulfiram creates an aversive reaction to alcohol consumption.

MAT is not FDA-approved or recommended as a primary treatment for stimulant use disorder, cannabis use disorder, or gambling disorder, though research into pharmacological agents for these conditions is ongoing.

How MAT Works: The Neurobiological Mechanism

To understand why medication is necessary for opioid use disorder — rather than simply willpower or counseling — it helps to understand what opioids do to the brain’s reward system.

What Opioids Do to the Brain

Repeated opioid use produces three overlapping neurobiological adaptations that medication-assisted treatment directly addresses:

• Mu-opioid receptor downregulation: The brain reduces mu-opioid receptor density in response to chronic opioid activation. The result is tolerance, more drug required to achieve the same effect, and a suppressed baseline reward capacity that makes normal pleasures feel flat.
• Locus coeruleus hyperactivity: The locus coeruleus, a noradrenergic brainstem nucleus, is suppressed during opioid intoxication. During withdrawal, it fires at dramatically elevated rates, producing the autonomic storm of opioid withdrawal: sweating, racing heart, anxiety, diarrhea, and muscle cramping.
• Mesolimbic dopamine dysregulation: The mesolimbic reward circuit is recalibrated by chronic opioid exposure. Drug-associated cues, people, places, sounds, emotional states, trigger dopamine surges through conditioned learning that produces intense craving even months after physical withdrawal resolves.

How MAT Medications Address These Mechanisms

MAT medications intervene at the receptor level to stabilize the neurobiological systems that opioids have dysregulated:

• Methadone and buprenorphine maintain mu-opioid receptor occupancy at sub-euphoric levels, preventing withdrawal, dampening craving, and reducing the locus coeruleus hyperactivity that drives the autonomic symptoms of withdrawal
• Naltrexone blocks mu-opioid receptors entirely, preventing opioids from producing euphoria and thereby extinguishing the conditioned dopamine response over time
• Acamprosate (for AUD) modulates NMDA glutamate receptor activity and GABA neurotransmission, counteracting the excitatory hyperactivity that sustains protracted alcohol craving after detox

MAT Medications for Opioid Use Disorder

The 3 FDA-Approved OUD Medications Compared

Medication	Type	How It Works	Dosing	Setting	Best For
Methadone	Full mu-opioid agonist	Activates opioid receptors to prevent withdrawal and blunt craving	Daily oral liquid	Federally certified OTP clinic only	Severe OUD, history of treatment failure, pregnancy
Buprenorphine (Suboxone, Sublocade)	Partial mu-opioid agonist	Partially activates receptors with ceiling effect reduces withdrawal and craving without full euphoria	Daily sublingual film/tablet or monthly injection (Sublocade)	Office-based prescribers (DATA 2000 waiver holders)	Moderate to severe OUD, outpatient setting
Naltrexone (Vivitrol)	Mu-opioid antagonist	Blocks all opioid receptor activity prevents euphoria from any opioid use	Monthly injectable (Vivitrol) or daily oral (Revia)	Any licensed prescriber	Motivated patients after full opioid detox, no current opioid use required

Methadone

Methadone is a full mu-opioid receptor agonist that has been used in OUD treatment since the 1960s. It activates opioid receptors at sub-euphoric concentrations when taken as prescribed, eliminating withdrawal and suppressing craving through stable receptor occupancy. Methadone has a long half-life of 24 to 36 hours, meaning once-daily dosing provides 24-hour coverage.

Methadone must be dispensed through federally certified Opioid Treatment Programs (OTPs) patients attend the clinic daily (at least initially) for observed dosing. This setting provides consistent monitoring and access to counseling. Methadone is the only FDA-approved MAT medication for use during pregnancy.

Buprenorphine (Suboxone, Sublocade)

Buprenorphine is a partial mu-opioid receptor agonist with a ceiling effect at higher doses, additional buprenorphine does not produce additional euphoria or respiratory depression, making it substantially safer in overdose than methadone or full opioid agonists. Suboxone combines buprenorphine with naloxone to deter injection misuse.

Buprenorphine can be prescribed by office-based prescribers with appropriate DEA authorization, making it accessible through primary care, addiction medicine, and outpatient treatment settings like Right Choice Recovery’s programs. Sublocade is a monthly injectable buprenorphine formulation that eliminates daily dosing compliance requirements.

According to a Cochrane Database review by Mattick et al., buprenorphine maintenance significantly outperforms placebo for treatment retention and opioid use reduction, with outcomes comparable to methadone for many patient populations.

Naltrexone (Vivitrol)

Naltrexone is a full mu-opioid receptor antagonist it blocks opioid receptors completely, preventing any opioid from producing euphoric effects. Vivitrol, the monthly injectable form, provides sustained receptor blockade without daily compliance requirements. Naltrexone also blocks alcohol’s endorphin-mediated reward mechanism, making it the only FDA-approved medication for both OUD and AUD.

Naltrexone requires full opioid clearance before induction typically 7 to 10 days of opioid-free time to avoid precipitated withdrawal. It does not cause physical dependence and can be discontinued without tapering. Right Choice Recovery provides Vivitrol injections as part of its medication management programming.

MAT Medications for Alcohol Use Disorder

Three medications are FDA-approved for alcohol use disorder:

• Naltrexone (oral or Vivitrol injectable): Blocks mu-opioid receptor-mediated dopamine release triggered by alcohol, reducing the pleasurable reinforcement of drinking. Both daily oral and monthly injectable formulations are effective. Most appropriate for patients who want to reduce or stop drinking and have not had recent opioid use.
• Acamprosate (Campral): Modulates NMDA glutamate and GABA-A receptor activity to counteract the neurochemical imbalance produced by chronic alcohol use. Reduces protracted withdrawal craving in patients who have already achieved abstinence from alcohol. Does not reduce the pleasurable effects of alcohol if drinking resumes most effective as an abstinence maintenance tool after detox.
• Disulfiram (Antabuse): Inhibits aldehyde dehydrogenase, blocking alcohol metabolism and causing acetaldehyde accumulation if alcohol is consumed. The resulting flushing, nausea, palpitations, and hypotension create a powerful aversive consequence for drinking. Requires complete abstinence and is most effective in patients with strong external motivation and structured monitoring.

Who Qualifies for MAT?

Eligibility Criteria

MAT is appropriate for adults with a confirmed diagnosis of opioid use disorder or alcohol use disorder, as defined by the DSM-5 diagnostic criteria. A comprehensive clinical evaluation determines which medication best fits the individual’s clinical presentation, treatment history, and recovery goals.

Factors that inform MAT medication selection:

• Severity of physical dependence: Severe OUD with high-dose, long-duration use benefits most from the continuous receptor stabilization methadone or buprenorphine provides
• Opioid clearance status: Naltrexone requires confirmed opioid-free status before induction; buprenorphine and methadone can be initiated during active withdrawal
• Pregnancy: Methadone is the only FDA-approved OUD medication for pregnant women; buprenorphine may be considered with specific clinical evaluation
• Co-occurring mental health conditions: Depression, PTSD, and anxiety disorders are evaluated and addressed concurrently through integrated behavioral health treatment
• Previous treatment history: Prior buprenorphine or methadone experience, MAT diversion history, and response to behavioral therapy inform medication selection

Common Misconceptions About MAT

“MAT is just replacing one addiction with another.” MAT medications are prescribed by licensed clinicians in monitored doses that stabilize brain chemistry without producing the euphoric surge and behavioral cycles that characterize addiction. Per SAMHSA, MAT is a legitimate, evidence-based treatment no different philosophically from using medication for any chronic condition.

“You’re not really sober if you’re on MAT.” SAMHSA, NIDA, and the major addiction medicine professional bodies recognize medication-assisted recovery as full sobriety. Using MAT does not disqualify a person from participation in 12-step programs or other recovery communities, though individual group cultures vary.

“MAT is only for severe cases.” MAT is appropriate across the severity spectrum of OUD and AUD. Earlier intervention with medication produces better outcomes because it reduces cumulative exposure to the neurobiological damage of active addiction.

MAT at Right Choice Recovery

Right Choice Recovery provides medication-assisted treatment as a core component of its outpatient programming for opioid use disorder and alcohol use disorder in Dayton, New Jersey.

Partial Care Program

The partial care program provides the highest outpatient level of MAT-integrated care. Patients receive medication management appointments, weekly individual therapy, group CBT and DBT programming, and relapse prevention as part of a five-day-per-week structure. Vivitrol injections are administered on-site.

Intensive Outpatient Program

The intensive outpatient program combines medication management with morning and evening group scheduling, allowing patients to maintain work and family obligations while receiving structured MAT-integrated recovery support. Same-day clinical assessments are available for all incoming patients.

References

1. Substance Abuse and Mental Health Services Administration. (2024). Medications for opioid use disorder: Treatment Improvement Protocol (TIP) 63. https://www.samhsa.gov/
2. National Institute on Drug Abuse. (2024). Medications to treat opioid use disorder. https://nida.nih.gov/
3. Centers for Disease Control and Prevention. (2024). Medication-assisted treatment for opioid use disorder. https://www.cdc.gov/
4. Mattick, R. P., et al. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, 2, CD002207.
5. World Health Organization. (2009). Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. https://www.who.int/
6. American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.).
7. American Society of Addiction Medicine. (2020). National practice guideline for the treatment of opioid use disorder.